








FIG. 2C




FIG. 2D






FIG. 3



Retention time

FIG. 4A

Effect of Y9 and purified compounds
on AR activity of 22RV1 cells with DHT




FIG. 4B

Effect of Y1830 and purified compounds
on AR activity of 22RV1 cells with DHT





FIG. 4C






FIG 5A.





FIG 5B



PC3-AR-luc C1 DEX




FIG 5C

FIG. 5D





FIG. 5E

FIG. 5F




FIG. 5G

SUBSTITUTE SHEET (RULE 26)

FIG. 6A





FIG. 6B




SUBSTITUTE SHEET (RULE 26)


FIG. 6C

LNCaP cells

LNCaP DHT




LNCaP DHT






SUBSTITUTE SHEET (RULE 26)

FIG. 6D


GR overexpressing LNCaP cell



SUBSTITUTE SHEET (RULE 26)

FIG. 7AFIG. 7BFIG. 7C

LNCaP GR transfected cells
growth for 4 day

FIG. 7D

PC3 4-day relative growth
w or w/o DEX 50nM


FIG. 7E

FIG. 8A




FIG. 8B

MG132




FIG. 9A




FIG. 9B
MG132-5uM




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12A

	MCF7	T47D	MDAMB 453	MDAMB 231
ER	+	+	-	-
PR	+	+	-	-
HER2	-	-	+	-
p53	wt	mut	mut	mut






FIG. 12B



SUBSTITUTE SHEET (RULE 26)

FIG. 12C



SUBSTITUTE SHEET (RULE 26)

FIG. 13




FIG. 14

Inhibitory profile for IDO and AR is different





FIG. 15A

* $P < 0.05$ in t-test analysis

Y1830, 500mg/kg, PO, BID.

RGA containing fraction 2.2mg/kg at
equivalent dose to Y1830. PO

FIG. 15B